UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000037150 |
|---|---|
| Receipt number | R000042336 |
| Scientific Title | Examination of efficacy and safety treated by Mirogabalin in patients with peripheral neuropathy in Orthopaedic disease |
| Date of disclosure of the study information | 2019/06/25 |
| Last modified on | 2019/06/24 16:55:14 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Examination of efficacy and safety treated by Mirogabalin in patients with peripheral neuropathy in Orthopaedic disease
Acronym
Examination of efficacy and safety treated by Mirogabalin in patients with peripheral neuropathy in Orthopaedic disease
Scientific Title
Examination of efficacy and safety treated by Mirogabalin in patients with peripheral neuropathy in Orthopaedic disease
Scientific Title:Acronym
Examination of efficacy and safety treated by Mirogabalin in patients with peripheral neuropathy in Orthopaedic disease
Region
| Japan |
Condition
Condition
Patients with peripheral neuropathy in Orthopaedic diseases
Classification by specialty
| Orthopedics |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
The aim of this study is to examine the efficacy and safety treated by Mirogabalin in patients with peripheral neuropathy in Orthopaedic diseases for 6 months
Basic objectives2
Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Percent changes from the baseline values prior to treatment
Key secondary outcomes
Base
Study type
Interventional
Study design
Basic design
Parallel
Randomization
Randomized
Randomization unit
Individual
Blinding
Open -but assessor(s) are blinded
Control
Active
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
2
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
Mirogabalin group
Interventions/Control_2
Pregabalin group
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 100 | years-old | >= |
Gender
Male and Female
Key inclusion criteria
1 More than 40mm of VAS or 40 points of NRS in patients with peripheral neuropathy
2 Patients who agree with this study
Key exclusion criteria
1 Patients who have taken Mirogabalin or Prerogabalin before
2 Patients who are allergic to Mirogabalin or Prerogabalin
3 Others
Target sample size
60
Research contact person
Name of lead principal investigator
| 1st name | Yukio |
| Middle name | |
| Last name | Nakamura |
Organization
Shinshu University School of Medicine
Division name
Dept. of Orthopaedic Surgery
Zip code
3908621
Address
Asahi 3-1-1, Matsumoto 3908621, Japan
TEL
0263372659
yxn14@aol.jp
Public contact
Name of contact person
| 1st name | Yukio |
| Middle name | |
| Last name | Nakamura |
Organization
Shinshu University School of Medicine
Division name
Dept. of Orthopaedic Surgery
Zip code
3908621
Address
Asahi 3-1-1, Matsumoto 3908621, Japan
TEL
0263372659
Homepage URL
yxn14@aol.jp
Sponsor or person
Institute
Dept. of Orthopaedic Surgery
Shinshu University School of Medicine
Institute
Department
Personal name
Funding Source
Organization
Shinshu University School of Medicine
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Shinshu University School of Medicine
Address
Asahi 3-1-1, Matsumoto 3908621, japan
Tel
0263-37-2572
mdrinri@shinshu-u.ac.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2019 | Year | 06 | Month | 25 | Day |
Related information
URL releasing protocol
Publication of results
Partially published
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Preinitiation
Date of protocol fixation
| 2019 | Year | 06 | Month | 17 | Day |
Date of IRB
| 2019 | Year | 06 | Month | 04 | Day |
Anticipated trial start date
| 2019 | Year | 06 | Month | 25 | Day |
Last follow-up date
| 2024 | Year | 06 | Month | 24 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2019 | Year | 06 | Month | 24 | Day |
Last modified on
| 2019 | Year | 06 | Month | 24 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000042336
